repeated administration a problem which occurs with currently approved LHRH agonistsCurrently there are no GnRH antagonists commercially approved beyond 1 monthVeru is also advancing new drug form ID: 857937
Download Pdf The PPT/PDF document "prostate cancer supportive care today an..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1 prostate cancer supportive care, today a
prostate cancer supportive care, today announced that it has added to its robust prostate cancerdrug development pipeline, a proprietary biologic drug candidate, VERU-100, for the treatment ofhormone sensitive advanced prostate cancer, an established multi-billion-dollar global market. VERU-100 was internally developed in collaboration with Drug Delivery Experts, LLC of San Diego,California (DDE Labs).ÒThe target product proÞle for VERU-100 is most compelling having a number of advantages overcurrently available androgen deprivation therapies. VERU-100 is a long-acting gonadot
2 ropin-releasing hormone (GnRH) antagonis
ropin-releasing hormone (GnRH) antagonist designed to be administered as a small volume repeated administration --- a problem which occurs with currently approved LHRH agonists.Currently, there are no GnRH antagonists commercially approved beyond 1 month.Veru is also advancing new drug formulations in its specialty pharmaceutical pipeline addressingunmet medical needs in urology such as the TadalaÞl and Finasteride Combination (TADFINª) forthe co-administration of tadalaÞl 5mg and Þnasteride 5mg dosed daily for benign prostatichyperplasia (BPH). TadalaÞl (CIALIS¨) is currently
3 approved for treatment of BPH and erect
approved for treatment of BPH and erectiledysfunction and Þnasteride is currently approved for treatment BPH (Þnasteride 5mg PROSCAR¨)and male pattern hair loss (Þnasteride 1mg PROPECIA¨). The co-administration of tadalaÞl andÞnasteride has been shown to be more effective for the treatment of BPH than by Þnasteride alone.Veru is also developing Tamsulosin DRS granules and Tamsulosin XR capsules which areformulations of tamsulosin, the active ingredient in FLOMAX¨, which Veru has designed to avoid uncertainties related to its business and are made as of the date of this releas
4 e. The Companyassumes no obligation to u
e. The Companyassumes no obligation to update any forward-looking statements contained in this release becauseof new information or future events, developments or circumstances. Such forward-lookingstatements are subject to known and unknown risks, uncertainties and assumptions, and if any suchrisks or uncertainties materialize or if any of the assumptions prove incorrect, our actual resultscould differ materially from those expressed or implied by such statements. Factors that may causeactual results to differ materially from those contemplated by such forward-looking stateme